Alchemia raises $5m in share purchase plan
Wednesday, 14 December, 2005
Brisbane biopharma Alchemia (ASX:ACL) has successfully raised AUD$5 million, closing its share purchase plan heavily oversubscribed. Earlier this month the company raised $14.6 million through a share placement. The funds will be used to accelerate Alchemia's drug discovery program, specifically to progress anti-cancer drug candidate ACL16907 from preclinical status to the completion of phase II clinical trials in 2008, and to advance an eye-disease candidate for age-related macular degeneration to the end of phase I clinical trials by 2007-08.
It will also be used to help identify new preclinical candidates using Alchemia's drug discovery platform
The offer of up to 4,545 shares at $1.10 per share was made to all registered shareholders in Australia and New Zealand on November 3, and taken up by more than 65 per cent of eligible shareholders. At time of writing Alchemia shares were trading at $1.19.
Oxytocin analogue treats chronic abdominal pain
Researchers have developed a new class of oral painkillers to suppress chronic abdominal pain,...
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
